The NDA submission in Q4 2026 is the next catalyst. Investors should monitor whether the FDA accepts the filing and whether the subgroup and survival data are sufficient to overcome the missed primary endpoint. A CRL on safety/efficacy grounds would be highly bearish; approval would be transformative for this early-stage biotech.
Price Chart
Executive Summary
Rafael Holdings announced topline Phase 3 results for Trappsol Cyclo in Niemann-Pick Disease Type C. The primary endpoint missed statistical significance (p=0.19), but a prespecified subgroup (83% of patients) on background miglustat/leucine showed a statistically significant benefit (p=0.046). The company remains on track for an NDA submission in Q4 2026, citing supportive survival data from an external control analysis.
Key Facts
- Phase 3 TransportNPC study (n=94) missed primary endpoint: LS mean change 0.46 vs 1.28 points, p=0.19
- Prespecified analysis in patients on background miglustat/leucine (83% of study) showed statistically significant benefit: difference -1.11 points, p=0.046
- Overall survival analysis in infantile-onset NPC showed 85% reduction in mortality risk vs INPDR controls (HR=0.154, p=0.044) and 94% reduction vs expanded historical controls (HR=0.057, p=0.0008)
- NDA submission on track for Q4 2026 based on pre-NDA meeting with FDA
- Safety profile consistent with prior studies; serious TEAEs higher in Trappsol group (35.9% vs 16.7%) but treatment-related serious TEAEs similar (3.1% vs 3.3%)
Financial Impact
Rafael Holdings is a pre-revenue biotech with no approved products; Trappsol Cyclo is its lead candidate. The mixed Phase 3 data (missed primary but positive subgroup and survival) creates binary regulatory risk for the NDA submission.
Risk Factors
- Primary endpoint miss may lead to FDA rejection or requirement for additional trials
- Serious TEAE imbalance (35.9% vs 16.7%) could raise safety concerns during regulatory review
- Hearing-related adverse events, including one case of severe bilateral deafness, may be a safety signal
- Reliance on subgroup and external control survival analyses may not satisfy FDA evidentiary standards
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3371740 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 8-K | $1.32 | awaiting T+20 | — | $1.18 (−10.61%) |
Sep 30, 2026 26d ago | Press Release | $1.32 | awaiting T+20 | — | $1.18 (−10.61%) |
Aug 18, 2026 9w ago | Institutional Cluster | $1.86 $2.10 | ▲ +12.90% | ▲ +13.89% | $1.18 (−36.56%) |
Jun 11, 2026 19w ago | 8-K | $2.12 $2.27 | ▲ +7.08% | ▲ +5.18% | $1.18 (−44.34%) |
Jun 10, 2026 19w ago | 8-K | $1.78 $2.27 | ▲ +27.53% | ▲ +23.91% | $1.18 (−33.71%) |
Jun 10, 2026 19w ago | Press Release | $1.78 $2.27 | ▲ +27.53% | ▲ +23.91% | $1.18 (−33.71%) |
Apr 22, 2026 26w ago | 8-K | $1.30 $1.35 | ▲ +3.85% | ▲ +0.68% | $1.18 (−9.23%) |
Mar 16, 2026 32w ago | Press Release | $1.32 $1.22 | ▼ −7.58% | ▼ −11.88% | $1.18 (−10.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers